Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Acquires 122,221 Shares of Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn acquired 122,221 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the transaction, the chief financial officer now owns 151,077 shares in the company, valued at $67,984.65. The trade was a 423.55 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Quoin Pharmaceuticals Trading Down 1.6 %

QNRX opened at $0.55 on Friday. The business’s 50 day moving average is $0.68 and its 200-day moving average is $0.63. The stock has a market cap of $2.78 million, a PE ratio of -0.14 and a beta of 1.79. Quoin Pharmaceuticals, Ltd. has a twelve month low of $0.43 and a twelve month high of $6.18.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.